Matija Snuderl
Small-cap, biotech, healthcare, growth

Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin

I have long planned to write my opinion on Cellceutix (OTCQB:CTIX), which I consider one of the most exciting oncology-focused biotech companies. Despite the usual risks of an early-stage biotech, I find their p53 activator compound Kevetrin one of the most interesting things to follow.

However, when Cellceutix acquired PolyMedix assets from bankruptcy in September 2013, I was not sure what to make out of it. A biotech company developing cancer drugs is buying an antibiotic company's assets? I must admit that my impression was not positive at first. I prefer when an early-stage biotech company stays focused on the key compounds. After some time, I analyzed the acquisition in more depth and started developing a sneaking suspicion...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details